For the quarter ending 2025-09-30, ACRS made $3,299,000 in revenue. -$14,499,000 in net income. Net profit margin of -439.50%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 3,299,000 | 1,777,000 | 1,455,000 | 5,804,000 |
| Cost of revenue | 538,000 | 515,000 | 506,000 | 757,000 |
| Research and development | 13,028,000 | 11,449,000 | 11,584,000 | 9,435,500 |
| General and administrative | 4,871,000 | 5,386,000 | 6,139,000 | 5,899,000 |
| In-process research and development | - | - | - | 21,726,250 |
| Licensing | 1,911,000 | 1,335,000 | 1,010,000 | 26,539,750 |
| Revaluation of contingent consideration | 100,000 | 1,500,000 | 300,000 | 750,000 |
| Total costs and expenses | 20,448,000 | 20,185,000 | 19,539,000 | 65,107,500 |
| Loss from operations | -17,149,000 | -18,408,000 | -18,084,000 | -59,303,500 |
| Interest income | 1,819,000 | 2,018,000 | 2,166,000 | 25,947,250 |
| Non-cash royalty income | 716,000 | 961,000 | 833,000 | 340,000 |
| Total other income | 2,535,000 | 2,979,000 | 2,999,000 | 26,287,250 |
| Loss before income taxes | - | - | - | -33,016,250 |
| Net loss | -14,614,000 | -15,429,000 | -15,085,000 | -56,746,500 |
| Unrealized gain on marketable securities, net of tax of 0 | 115,000 | 48,000 | 337,000 | -294,000 |
| Total other comprehensive income | 115,000 | 48,000 | 337,000 | -294,000 |
| Comprehensive loss | -14,499,000 | -15,381,000 | -14,748,000 | -57,040,500 |
| Earnings per share, basic | -0.12 | -0.13 | -0.12 | -0.725 |
| Earnings per share, diluted | -0.12 | -0.13 | -0.12 | -0.725 |
| Weighted average number of shares outstanding, basic | 122,619,311 | 122,580,967 | 122,390,303 | -32,688,233 |
| Weighted average number of shares outstanding, diluted | 122,619,311 | 122,580,967 | 122,390,303 | -32,688,233 |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)